ISSN |
2307-8960 (online) |
Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Retrospective Study |
Article Title |
Risk factors for de novo hepatitis B during solid cancer treatment
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Rie Sugimoto, Masayuki Furukawa, Takeshi Senju, Yoshihusa Aratake, Mototsugu Shimokawa, Yuki Tanaka, Hiroki Inada, Tatsuya Noguchi, Lingaku Lee, Masami Miki, Yuji Maruyama, Risa Hashimoto and Terumasa Hisano |
ORCID |
|
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
Eisai Corporation |
HHCS20181030011 |
|
Corresponding Author |
Rie Sugimoto, MD, PhD, Chief Doctor, Department of Hepato-Biliary-Pancreatology, National Hospital Organization Kyushu Cancer Center, 3-1-1 Notame Minami-ku, Fukuoka City 811-1395, Fukuoka Prefecture, Japan. sugirie5@yahoo.co.jp |
Key Words |
Hepatitis B; Reactivation; Solid cancer treatment; Digestion and absorption organ; Hepatitis B surface antibody; Hepatitis B core antibody titer |
Core Tip |
Hepatitis B virus (HBV) reactivation in patients during cancer treatment is a critical issue. We retrospectively reviewed the expression of HBV DNA in 1040 patients undergoing anticancer treatment for various types of solid tumors at our institution and examined the patient and disease information. Among the 1040 patients, 938 had both hepatitis B core antibodies (HBcAbs) and hepatitis B surface antibodies (HBsAbs), while 102 had only HBsAbs. We confirmed HBV DNA expression in 44 patients (4.7%, 44/938), all of whom were HBcAb–positive patients. HBV DNA expression was detected before treatment in 9 patients and after treatment in 35 patients. A comparison of the treatments in patients with reactivation and those in patients without reactivation revealed no differences in treatment between groups. However, multivariate analysis identified both a high HBcAb titer and cancers in organs involved in digestion and absorption (such as the oral cavity, esophagus, stomach, colon, and others) as independent factors that contributed to HBV reactivation. Our findings may help identify a subset of cancer patients undergoing treatment that should be monitored for HBV reactivation. |
Publish Date |
2020-12-19 16:08 |
Citation |
Sugimoto R, Furukawa M, Senju T, Aratake Y, Shimokawa M, Tanaka Y, Inada H, Noguchi T, Lee L, Miki M, Maruyama Y, Hashimoto R, Hisano T. Risk factors for de novo hepatitis B during solid cancer treatment. World J Clin Cases 2020; 8(24): 6264-6273 |
URL |
https://www.wjgnet.com/2307-8960/full/v8/i24/6264.htm |
DOI |
https://dx.doi.org/10.12998/wjcc.v8.i24.6264 |